262 related articles for article (PubMed ID: 32402357)
21. Combined modality treatment of non-small-cell lung cancer.
Westeel V; Depierre A
Am J Respir Med; 2003; 2(6):477-90. PubMed ID: 14719987
[TBL] [Abstract][Full Text] [Related]
22. Combined modality therapy of non-small cell lung cancers.
Juretic A; Sobat H; Samija M
Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
[TBL] [Abstract][Full Text] [Related]
23. Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents.
Belani CP; Ramanathan RK
Chest; 1998 Jan; 113(1 Suppl):53S-60S. PubMed ID: 9438691
[TBL] [Abstract][Full Text] [Related]
24. Role of chemotherapy in stages I to III non-small cell lung cancer.
Strauss GM
Chest; 1999 Dec; 116(6 Suppl):509S-516S. PubMed ID: 10619521
[TBL] [Abstract][Full Text] [Related]
25. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
Hosoya K; Fujimoto D; Kawachi H; Sato Y; Kogo M; Nagata K; Nakagawa A; Tachikawa R; Hiraoka S; Kokubo M; Tomii K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):275-280. PubMed ID: 31201490
[TBL] [Abstract][Full Text] [Related]
26. Treatment of lung cancer.
Gadgeel SM; Ramalingam SS; Kalemkerian GP
Radiol Clin North Am; 2012 Sep; 50(5):961-74. PubMed ID: 22974781
[TBL] [Abstract][Full Text] [Related]
27. Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.
Bott MJ; Patel AP; Crabtree TD; Morgensztern D; Robinson CG; Colditz GA; Waqar S; Kreisel D; Krupnicka AS; Patterson GA; Broderick S; Meyers BF; Puri V
Ann Thorac Surg; 2015 Jun; 99(6):1921-8. PubMed ID: 25912748
[TBL] [Abstract][Full Text] [Related]
28. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
29. Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation.
Isobe K; Hata Y; Sakaguchi S; Sato F; Takahashi S; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Mitsuda A; Terahara A; Shibuya K; Takagi K; Homma S
Asia Pac J Clin Oncol; 2012 Sep; 8(3):260-6. PubMed ID: 22897895
[TBL] [Abstract][Full Text] [Related]
30. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
Choy H; Gerber DE; Bradley JD; Iyengar P; Monberg M; Treat J; Govindan R; Koustensis A; Barker S; Obasaju C
Lung Cancer; 2015 Mar; 87(3):232-40. PubMed ID: 25650301
[TBL] [Abstract][Full Text] [Related]
31. Current treatment paradigms for locally advanced non-small cell lung cancer.
Rigas JR; Kelly K
J Thorac Oncol; 2007 Jun; 2 Suppl 2():S77-85. PubMed ID: 17589303
[TBL] [Abstract][Full Text] [Related]
32. Stage III Non-small Cell Lung Cancer.
Rusch VW
Semin Respir Crit Care Med; 2016 Oct; 37(5):727-735. PubMed ID: 27732994
[TBL] [Abstract][Full Text] [Related]
33. Multimodality therapy for stage III non-small-cell lung cancer.
Farray D; Mirkovic N; Albain KS
J Clin Oncol; 2005 May; 23(14):3257-69. PubMed ID: 15886313
[TBL] [Abstract][Full Text] [Related]
34. A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
Harris JP; Patel MI; Loo BW; Wakelee HA; Diehn M
Lung Cancer; 2017 Jun; 108():173-182. PubMed ID: 28625632
[TBL] [Abstract][Full Text] [Related]
35. Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer.
Adelstein DJ; Rice TW; Rybicki LA; Larto MA; Koka A; Taylor ME; Olencki TE; Peereboom DM; Budd GT
Am J Clin Oncol; 1999 Jun; 22(3):237-42. PubMed ID: 10362328
[TBL] [Abstract][Full Text] [Related]
36. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
37. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
38. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
Davies M; Duffield E
Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
40. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
